Wednesday, July 3, 2013

Rhode Island Board of Pharmacy Meeting July 03, 2013

- No comments:
Labels: ,

Oregon Board of Pharmacy Rule Changes


July 1, 2013
On June 12, 2013 the Board amended the following fees: Reciprocity, County Health Clinics, Family Planning Clinics, Hospital Drug Rooms, Correctional Facilities, Prophylactic/Contraceptive Outlets, Retail and Institutional Drug Outlets, Home Dialysis Drug Outlets and all Controlled Substance registration fees.
The Board implemented a temporary fee reduction for these fees as allowed by ORS 291.055(3) due to an unexpected surplus in revenue. These fee reductions are in addition to the temporary pharmacist licensure fee reduction that went into effect on April 5, 2013.
Certificate and Order for Filing Temporary Administrative Rules - Effective July 1, 2013


June 27, 2013 Rulemaking Hearing
On Thursday, June 27, 2013 at 9:30AM, the Oregon Board of Pharmacy will conduct a rulemaking hearing on the following topics in Room 1A of the Portland State Office Building, 800 NE Oregon St., Portland, OR 97232. 
Notice of Rulemaking Hearing and Statement of Need
Remote Processing Drug Outlet rules provide minimum requirements of operation for centralized prescription processing by a pharmacy that processes drug orders on behalf of an Oregon pharmacy.
Central Fill Drug Outlet rules provide minimum requirements of operation for centralized prescription drug filling by a pharmacy that fills drug orders on behalf of an Oregon pharmacy.
Consulting or Drugless Pharmacy rules are intended to ensure that a consulting pharmacist may safely store records and protected health information in an Oregon licensed drugless pharmacy when engaged in Independent Pharmacy Practice.
 
Consulting Pharmacist Practice rules are amended to establish registration requirements for a consulting pharmacist that stores health protected records outside an Oregon licensed pharmacy.
Customized Patient Medication Packages rules are amended to include a waiver clause.
 
Manufacturer rules are amended to clarify that any compounded non-patient specific drug from an
out-of-state drug outlet may only be distributed into the state by an Oregon registered manufacturer.
 
Controlled Substance rules are amended to include certain synthetic cannabinoids and cathinone-type derivatives that are subject to abuse, and have no legitimate medical purpose.
quoted from here

- No comments:
Labels:

Ohio Board of Pharmacy May 6-8 2013 Minutes--including disciplinary actions

can be read here
- No comments:
Labels:

PCCA Compounding Courses


Class Schedule

Read course descriptions here.

Introductory Compounding Lab Boot Camp

  • Status: Sold out
  • Location: Houston, Texas
  • Date: August 12-13, 2013

Advanced Compounding Training Program - Fall 2013 (10-Week Online Component and Lab)

Veterinary Compounding Training Program - Fall 2013 (10-Week Online Component and Lab)

Veterinary Compounding Training Program - Fall 2013 (10-Week Online Component ONLY)

- No comments:
Labels: , ,

Tuesday, July 2, 2013

Troubled pharmacy stops trading due to contaminated product

- No comments:

California Pharmacy Association Compounders Day 2013 CE

Compounders Day 2013
Saturday September 28th, 2013

Compounders Day is a unique venue that offers pharmacists and pharmacy technicians practicing in a compounding environment to meet and network with their colleagues and compounding vendors. Earn up to 6 hours of CE from educational programs that are selected by compounding pharmacists and tailored to your specific interests.  
Join us for a day and earn 6 CE hours:
  • Erectile Dysfunction & Female Libido
  • Quality Control and Personnel Validation
  • E-Marketing
  • Regulatory Update: Late Breaking Federal and State Update
    • Panelists:
    • David Miller, IACP Executive Vice President and CEO
    • Elizabeth Scott Russell, NABP Government Affairs Manager
    • Tony Park, California Pharmacy Law

Registration Fees
Online Registration (available until 09-20-2013)
More information found here
  • CPhA Pharmacist Member: $229
  • CPhA Non-Member $495 (Includes CPhA Membership!)
  • Technician CPhA Member: $99
  • Technician CPhA Non-Member: $199
  • Student: $59
On-site Registration
  • CPhA Pharmacist Member: $329
  • CPhA Non-Member $595 (Includes CPhA Membership!)
  • Technician CPhA Member: $99
  • Technician CPhA Non-Member: $199
  • Student: $59

Click Here to Register Now!
- No comments:

Managing Drug Recalls in the Compounding Environment Stephen Speth, RPh, MS

July 2012 Of the 42 Class I recalls issued in 2011, only 14 required notification to the consumer or patient level; seven of these recalls were for injectable products that could have been used to prepare compounded sterile preparations (CSPs), yet in none of these cases did the recall notification direct the hospital to contact patients who may have received the recalled product.1 However, in certain situSations, patient contact is required2 and if the pharmacy has no method by which to identify specific product lot numbers used in the preparation of CSPs, attempts at such contact will not only be unwieldy, they will also affect many more patients than would realistically be necessary. Imagine the following scenario, which may seem all too familiar.
Continue to read here
- No comments:

07-02-2013 | 15:10 PM Author: John Stahl The Blessing and the Curses of Compounded Drugs: Insurer Pulls Coverage Following Meningitis Outbreak


By John Stahl, Esq.
The FDA website defines “pharmacy compounding” as “a practice in which a licensed pharmacist combines, mixes, or alters ingredients in response to a prescription to create a medication tailored to the medical needs of an individual patient.” A simpler way of understanding this procedure is that a medical care provider determines that someone would benefit more from a customized medication than an “off-the-rack” drug, and the compounding pharmacy fills the prescription for that “made-to-fit” product.
The portion of the FDA’s description that states that “pharmacy compounding, if done properly, can serve an important public health need if a patient cannot be treated with an FDA-approved medication” illustrates the blessing and the curses regarding these hybrid medications.
The blessing is that a compounded drug is “tailored to the medical needs of an individual patient.” This has particular importance to workers’ compensation because the myriad of factors, such as long-term exposure to toxic substances and a simultaneous combination of physical injuries, often hinders determining the optimal “drug cocktail” for a claimant.
The curses include that compounded drugs have not undergone the FDA approval process and that they are not always “done properly.” Additionally, the pharmacies where the compounding occurs overall are subject to less stringent regulation than the manufacturing of the individual compounded drugs, which require the aforementioned FDA approval, that pharmacists combine to make the custom concoctions.
Another portion of the FDA website concisely summarizes more general concerns regarding compounded drugs. Serious risks associated with that practice include:
  • · Improperly compounded drugs lacking appropriate potency;· Patients using a properly prepared but ineffective compounded drug rather than an effective FDA-approved medication;· Pharmacists who are not properly trained to compound drugs combining drugs that should not be compounded; and· Compound pharmacies that lack appropriate levels of quality control.
Continue reading reading here
- No comments:

Dr. Kathy senate bill 959 part 1 podcast

View here
- No comments:

Product Safety Information FACTREL - Veterinarians

Product Safety Information FACTREL - Veterinarians
- No comments:
Subscribe to: Posts (Atom)